Compare WTI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTI | STTK |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.5M | 652.4M |
| IPO Year | 2004 | 2020 |
| Metric | WTI | STTK |
|---|---|---|
| Price | $3.99 | $5.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $4.23 | ★ $15.40 |
| AVG Volume (30 Days) | ★ 3.5M | 1.1M |
| Earning Date | 10-29-2026 | 11-13-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $487,096,000.00 | $1,000,000.00 |
| Revenue This Year | $18.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $1.72 |
| 52 Week High | $5.08 | $8.33 |
| Indicator | WTI | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 41.15 |
| Support Level | $3.49 | $5.19 |
| Resistance Level | $4.24 | $7.66 |
| Average True Range (ATR) | 0.22 | 0.36 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 60.54 | 27.58 |
W&T Offshore Inc is an an independent oil, NGL and natural gas producer with all of its operations offshore in the Gulf of America. The company is active in the exploration, development and acquisition of oil and natural gas properties. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion. The company has its operations in Mississippi Canyon; Ewing Bank; Ship Shoal; Garden Banks; and Mobile Bay Complex.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.